Semaglutide

Long-acting selective GLP-1 receptor agonist for weight loss and glycemic control.

Quick Reference

Dose: 0.25 → 2.4 mg
Frequency / schedule: Once weekly
Route: Subcutaneous
Timing: Same day each week (morning or evening)
Fasting: Not required — can be taken with or without food
Cycle: Ongoing
Time off: Weight regain common on stop
Common vial strengths: 2 mg, 5 mg, 10 mg research vials

How this works

Semaglutide is a long-acting GLP-1 analog modified for albumin binding and DPP-4 resistance (half-life ~7 days). It activates GLP-1 receptors to suppress appetite via the hypothalamus, slow gastric emptying, enhance glucose-dependent insulin secretion, and suppress glucagon. Result: reduced energy intake and better blood-sugar control.

Benefits + side effects

Potential Benefits

Average ~15% weight loss
Significant HbA1c reduction
20% lower major cardiovascular events

Side Effects

GI effects (common, usually improve)
Rare pancreatitis / gallbladder issues
Thyroid C-cell tumor signal in rodent studies

Dosing / Protocol

Reference Protocol

Phase / week	Dose	Frequency	Timing	Notes
Weeks 1–4	0.25 mg	Once weekly	Same day	GI adaptation only
Weeks 5–8	0.5 mg	Once weekly	Same day	First therapeutic
Weeks 9–12	1.0 mg	Once weekly	Same day	Common diabetes dose
Weeks 13–16	1.7 mg	Once weekly	Same day	Approaching full dose
Maintenance	2.4 mg	Once weekly	Same day	Full weight-loss dose

Timing + Fasting Notes

- Inject on the same day and roughly the same time each week. - Food does not significantly affect absorption. - Evening dosing is popular so any nausea happens while sleeping.

Reconstitution

Common vial strengths2 mg, 5 mg, 10 mg research vials

Approved preparation example
5 mg vial + 2 mL BAC = 2.5 mg/mL. Calculate units carefully for lower starting doses.

Practical Reference

Storage: Lyophilized frozen or refrigerated; reconstituted refrigerated, use within 28 days
Route / injection context: Subcutaneous
Bloodwork / markers: HbA1c, weight, lipids, thyroid if indicated
Common vial strengths: 2 mg, 5 mg, 10 mg research vials
Cycle / time off: Ongoing · Weight regain common on stop
Practical notes: Research peptide — reconstitute yourself. Slow 4-week titration is mandatory for tolerability. Rotate sites.

References

Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine · 2021 · DOI 10.1056/NEJMoa2032183

CLINICAL TRIAL

Dataset reference context: STEP trials + SELECT trial

THE SIGNAL · SENT TWICE A MONTH

Stay ahead of the research without living on PubMed.

Peptide references, research worth knowing, new FEMETRIC tools, and meaningful testing updates. Twice a month. No daily emails.By subscribing, you agree to receive The Signal from FEMETRIC. Unsubscribe anytime.

Search Femetric